Library

Place of publication:
Journal of Neurology and Psychiatry, 3, 2014

Summary:
The purpose of the study is to analyze the effectiveness of the drug Mexidol in relation to the secondary prevention of ischemic stroke (AI). Material and methods. The results of the treatment of 3400 patients who were divided into 7 groups are analyzed: patients with cryptogenic AI, arterial hypertension, atrial fibrillation, metabolic syndrome, obstructive apnea/sleep hypnome, diabetes mellitus, vasculitis. Assessment of the effectiveness of therapy was based on the absence of repeated AI for 5 years of therapy. Results. Mexidol helps to reduce the frequency of repeated AI in both patients without concomitant pathological conditions, and in patients with arterial hypertension, obstructive apnea/sleep hypnome syndrome, vasculitis, diabetes mellitus, atrial fibrillation and metabolic syndrome. Conclusion. Further studies of the effectiveness of the use of Mexidol as a means of secondary prevention of AI are seemed very promising. Key words: stroke, secondary prevention, Mexidol.

Place of publication:
emergency medical care, 2, 2013

Summary:
114 patients with an isolated severe traumatic brain injury aged 18 to 55 years were examined and treated. The group I includes 61 surviving patient, in the II group-53 patients who died on the 3-and -15th day of the post-traumatic period. Patients of groups I and II received complex intensive therapy in accordance with the current protocols. Fifteen patients (subgroup I) were obtained as part of the complex therapy of Mexidol at a dose of 1200 mg/day for 7-10 days. Against the background of the use of Mexidol, the intensity of the processes of lipoperoxidation was reduced, the power of the cell antioxidant protection system remained at a sufficient level, and the earlier resolution of post -traumatic encephalopathy and the restoration of consciousness were observed. Against the background of treatment with Mexidol, a more favorable course of the early post-traumatic period, a decrease in complications (χ2 = 55.4; p <0.0001)-acute damage syndrome, DIC, acute cardiovascular failure and pneumonia are noted.

Place of publication:
Pharmacate No. 19 - 2012

Summary:
In a study that included 34 patients, the effectiveness of Mexidol's preparation in the correction of astheno-vegetative disorders was studied in persons who have suffered a mild craniocre trauma (LCHMT) and a concussion of the brain. The use of Mexidol as part of the complex therapy of these disorders made it possible to improve the results of treatment compared to the control group of patients who did not receive Mexidol. It is noted that the prescription of the drug is preferably at an earlier date from the moment of injury. A distinct therapeutic effect was obtained when using Mexidol in a daily dose of 375 mg in a tablet form for 28-30 days in the acute and intermediate periods of the LCCMT. Side effects and complications during therapy were not observed in any group. It is concluded that Mexidol can be used in the complex treatment of LCHMTs, a concussion of the brain and the correction of the post -compliance syndrome.

Place of publication:
Journal of Neurology and Psychiatry, 6, 2012

Summary:
in the structure of cerebrovascular pathology, the stroke occupies a leading place as one of the main causes of mortality and primary disability of the population. In the treatment of a stroke, in the acute period, measures are the measures to correct the impaired functions of the body and maintain the viability of the nervous tissue. In the recovery period, drugs are used that have an activating effect on neurotrophic and reparative processes, and secondary prophylaxis of stroke is carried out. It is known that brain ischemia is a multifactor pathological process that includes a decrease in energy products with a violation of active vehicles through cell membranes, excessive accumulation of excitoxic excitation mediators in brain structures, an increase in ionized calcium in neurons, hyperproduction of free radicals and activation of oxidant stress. To correct these changes, preparations with antihyplance and antioxidant properties are traditionally used, which include Mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate). Mexidol improves the metabolism of nervous tissue, it is also known that it affects the rheological properties of blood, reduces platelet aggregation, and has a hypolipidemic effect.

Place of publication:
Herald of intensive therapy, 2012, No. 3. Neuroreusterology

Summary:
annually in the world from a traumatic brain injury (ChMT), one and a half million people die, and 2.4 million become disabled. The frequency of the CCT in various regions of Ukraine is from 2.3 to 4.2% per year, and over the past 10 years has almost doubled. Missiles for a severe CCT is 40–70%, and in surviving patients, the full functional restoration of the central nervous system (central nervous system) is relatively rare.

Place of publication:
Medical alphabet. Emergency medicine 1/22

Summary:
Heddle-brain injury (ChMT) is one of the main reasons for the disability and death of the population. Moreover, mechanical damage to the central nervous system does not tend to decrease in the structure of diseases and injuries. According to WHO, the frequency of craniocre injury annually increases by 2%. In Russia, about 600,000 people receive a traumatic brain injury annually, of which about 50,000 die and the same number of disabled people (Gusev E.I., 2009). Mortality at a severe CMT, according to various estimates, ranges from 10 to 25%, and with the most severe forms reaches 65-70%. In the vast majority of victims (60%), a decrease in performance and disability (epileptic seizures, encephalopathy, paresis and paralysis, speech disorders and other neurological consequences) are observed as a result of injury.

Place of publication:
Bulletin of experimental biology and medicine, 2012, Appendix 1

Summary:
the use of Mexidol in a basic dose of 100 mg/day intramuscularly for 10 days is effective in the treatment of mild CITs, which is confirmed by positive neurological dynamics. In patients with a severe CCT, it is more advisable to use a 10-day treatment regimen with a mexidol at a dose of 200 mg/day intramuscularly with the subsequent transition to orally in a dose of 0.25 g 2 times a day for 4 weeks. Due to the good tolerance and the possibilities of intramuscular administration, Mexidol is an urgent drug in outpatient practice for the treatment and rehabilitation of patients of different age groups with the CCT.

Place of publication:
Stroke, 18, 2006

Summary:
patients with an ischemic stroke at the age of 45–85 years (51 people) entered the first 24 hours from the onset of the disease were included in the study. Mexidol was introduced at a dose of 300 mg/day 24 patients for 14 days from the beginning of the stroke. The placebo was introduced by 27 patients according to a similar scheme. A reliable advanced dynamics in the regression of neurological disorders on the NIH scale by the 14th day of the disease in the group of patients who received Mexol compared to the placebo group (p <0.05), as well as a reliable functional restoration (the dynamics of the clinical score on the Bartel scale at 21, were identified. -y day; p <0.05) in patients included in the study in the first 6 hours of the disease. The normalization of the functional activity of the brain was established in the treatment of Mexidol, including during acute pharmacological test. The complex of studies of the antioxidant system revealed an increase in the activity of its enzymes (superoxidsmutase, glutathioneperoxidase, glutathioneuctase) with the introduction of Mexidol compared to placebo. When analyzing the enzymes of the respiratory chain of mitochondria, an increase in the activity of succinate dehydrogenase was noted. Thus, a reliable clinical confirmation of the effectiveness of Mexidol was obtained in the acute period of ischemic stroke in the carotid system of an atherotrombotic or cardiembolic pathogenetic type, especially with an early (up to 6 hours) its appointment; The mechanisms of action of the drug (antihypoxic, antioxidant) in clinical conditions are clarified.

Summary:
intracranial hypertension syndrome (HDG) with distant consequences of closed cranial injury (CSMT) is manifested by organic and functional disorders of varying degrees of severity. The work uses a method for assessing the degree of ICG by measuring distances between the structures of the brain stem using magnetic resonance imaging. The calculation of the restriction index of the posterior cranial fossa made it possible to compare the data of 96 patients with the HRG, some of which received Mexidol, and 28 healthy volunteers. Observation was carried out during the year with a neurological examination in dynamics. A comparison of groups of patients with each other and with indicators of healthy individuals revealed reliable differences expressed to a lesser extent of the NCH after treatment with Mexidol. The study showed that the prolonged course use of Mexidol is an effective method of preventing episodes of increasing intracranial pressure in the remote period of mild ZchMT and can be recommended for wide use both in stationary and outpatient conditions.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 9, Issue. 2

Summary:
Mexol (ethylmethylhydroxypyridine succinate) is a modern neurometabolic drug that is increasingly used in neuropediatrics. The results of recent studies are considered, confirming the positive effects of pharmacotherapy with Mexidol in children with attention deficiency and hyperactivity disorder (ADHD), perinal lesions of the central nervous system (hypoxic-ischemic encephalopathy) and their consequences, neurological disorders and the delay in neuropsychic development after surgical interventions with congenital vices in congenital vices hearts, neuroinfections (meningitis, encephalitis), post -traumatic epilepsy. Given the unique multimodal action of Mexidol, it seems promising to expand the circle of indications for its use in neuropediatry, based on the results of new clinical studies, which will be organized in accordance with the modern principles of evidence -based medicine.

Keywords: Mexol (ethylmethylhydroxypyridine succinate), children, treatment, hypoxic and ischemic encephalopathy, attention deficiency syndrome, retention of neuropsychiatric development, meningitis, encephalitis, post-traumatic epilepsy.

Authors:
N.N. Zavadenko ¹ , N.Yu. Suvorinova ¹ , T.T. Batysheva ² , O.V. Bykova ² , A.N. Platonova ² , D.D. Gainetdinova ³ , E.V. Levitina ⁴ , V.V. Machines ⁵ , I.N. Vakula ⁶ , N.E. Maksimova ⁷

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² GBUZ "Scientific and practical center of children's psychoneurology of the Department of Health of Moscow", Moscow, Russia;
³ FSBEI in Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia;
⁴ FSBEI in Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia;
⁵ FSBEI in Ulyanovsk State University, Ulyanovsk, Russia;
⁶ LLC "Center for Professional Therapy", Krasnodar, Russia;

⁷FSBEI in the Tver State Medical University, Tver, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T.122, No. 4

Summary:
Purpose of the study. Evaluate the effectiveness and safety of two dosing modes of the drug Mexidol tablets covered with a film shell, 125 mg (NPK Farmasoft LLC, Russia), compared with placebo, in children with attention deficit (ADHD) from 6 to 12 years.

Material and methods. The study conducted the study in 14 clinical centers of the Russian Federation as a multicenter randomized double blind placebo-controlled in 3 parallel groups. The study was attended by 333 children aged 6 to 12 years with a confirmed diagnosis of ADHD, established in accordance with the criteria of the ICD-10 and DSM-5. After screening (up to 14 days), patients were randomized in 3 groups in a ratio of 1: 1: 1: Mexidol 125 mg 2 times a day, Mexidol 125 mg 1 time per day+placebo and placebo. The duration of treatment in all groups was 42 days. The study was completed by 332 children. The dynamics of the state was evaluated by the scales of the ADHD assessment and related disorders.

Results. Statistically significant changes in the amount of the total score on the subx “Inattentiveness”, “Hyperactivity impulsivity” of the ADHG assessment scale through 6 weeks of therapy in all three groups of the study (P <0.05). At the same time, between the groups of Mexol 125 mg 1 time per day+placebo and placebo, as well as between Mexol groups 125 mg 2 times a day and placebo, expressed statistically significant differences were observed (for the PP: P = 0.000308 and P = 0.000024 Accordingly, for the population FAS: P = 0.000198 and P = 0.000024, respectively), which indicates the superiority of the therapy with Mexidol. According to most secondary criteria for effectiveness (average changes in points on the “Inattention” Snap-IV scale, the average change in scores “Hyperactivity impulsiveness” of the SNAP-IV scale, the average change in the cones index of the SNAP-IV scale, the average change in the value On the ADHD Rating Scale IV scale, assessments on the scale of the general clinical impression of the severity of ADHD, estimates on the general clinical impression scale - improvement) were also obtained statistically significant differences (p <0.05) when comparing the treatment of Mexido with placebo. The results of a statistical analysis of the frequency of the occurrence of undesirable phenomena, indicators of laboratory tests, and a physically examination demonstrate the absence of significant differences between compared groups in basic safety indicators.

Conclusion. The treatment regimen with Mexol, tablets covered with a film shell, 125 mg 2 times a day, showed an advantage over Mexol's scheme tablets covered with a film shell, 125 mg once a day+placebo. A comparable nature of the security profiles of the studied dosing of the drug Mexidol and placebo was obtained.

Keywords: attention deficit syndrome with hyperactivity, inattention, hyperactivity, impulsiveness, children, pharmacotherapy, ethylmethydlhydroxypyridine succinate, Mexidol.

Place of publication:
Psychiatry and narcology, 2012

Summary:
Analyzing indicators of pain and incidence of children and adolescents of the Krasnodar Territory, in the class of mental disorders we observe stably high indicators among the child population and steady growth in adolescents. So, as of January 1, 2010, every 33 child and every 20 teenager is observed and treated in psychiatrists. In the nosological structure of mental disorders in children and adolescents of the region, mental disorders of a non-tochitotic nature prevail (69.65%), in 2nd place mental retardation (29.0%), psychoses are 1.35%. In the conditions of outpatient reception of a children's psychiatrist, cognitive and psychosomatic disorders are most common, as well as disorders of anxious-phobic spectrum on a residual-organic background, which is consistent with the data summarized by L.O. Badalyan, N.N. Zavadenko, T.Yu. Uspenskaya. The therapeutic strategies we use in children and adolescents combine psychotherapy and pharmacotherapy. The central link of therapeutic effect is psychocorrection and psychotherapy. Pharmacotherapy in child-teenage age is associated with a number of difficulties: it is difficult to convince parents to contact a psychiatrist and start a long-term medical treatment.

Place of publication:
neurology, 2012

Summary:
the problem of the health of the younger generation is one of the most relevant in both biological and social terms, and acquires special significance in modern conditions. Effective prevention and treatment of neurological diseases in children are important tasks. Children's neurological incidence in the Republic of Bashkortostan occupies one of the leading places not only in frequency, but also in the severity of clinical manifestations. Every 8th child out of 1000 is born with neurological dysfunction and from them every 10th child subsequently has a limitation of life. According to the United Nations, out of 120 million children with disabilities, a share of neurology accounts for 30%. In everyday clinical practice, decompensation of the consequences of the lesions of the nervous system in children, such as perinatal encephalopathy, the consequences of neuroinfections, the CTM, etc. are often found that it is possible that encephalopathy transferred in childhood create the basis for the formation of a number of diseases in an adult. When evaluating the outcome of brain damage, the risk of neuropsychiatric disorders with difficulty learning, emotional-volitional, psycho-regional disorders turned out to be extremely high and is 13-47%, therefore, attention should be paid to adequate systematic treatment, early rehabilitation measures from the first months of the child’s life. It is important to consider that in children the high adaptive capabilities of the body to restore impaired functions are much more expressed than in adults, and allow us to exclude or minimize the severity of disability.

Place of publication:
Bulletin of experimental biology and medicine, 2012, Appendix 1

Summary:
Analysis of the obtained data allows us to conclude that the need to use Mexidol when correcting various options for vegetative dysregulation. The identified characteristics do not contradict the literature. Thanks to its mechanism of action (antioxidant, membrane) and a wide range of pharmacological effects (cerebrotective, anti -hypoxic, tranquilizing, anti -stressful, nootropic, vegetative, anticonvulsant; improvement and stabilization of the brain metabolism and blood supply to the brain; correction of disorders in regulatory and microcircular systems; Improving rheological properties blood, suppression of platelets; activation of the immune system), Mexidol affects the main links of pathogenesis of various diseases associated with the processes of free radical oxidation, including at vegetative disorders. In addition, taking into account the ability of Mexidol to potentiate the action of other centrally active substances, it is optimal to use it in a complex approach to the treatment of autonomic dysregulation syndrome.

Key words: young age, autonomic disorders, vegetological research, Mexidol.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
the study is devoted to the assessment of the effectiveness of Mexidol in the correction of school adaptation of children with the syndrome of attention deficit with hyperactivity. School adaptation was evaluated according to the developed methodology (before and after treatment with Mexidol). 20 patients received complex treatment with the use of Mexidol (experimental group) and 23 patients without Mexidol (control group). Improving school adaptation was noted in 74% of patients of the experimental group and in 12% of patients of the control group.

Key words: attention deficit syndrome with hyperactivity, psychological correction, adaptation, Mexidol.